Literature DB >> 9579027

Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.

A Bendele1, J Seely, C Richey, G Sennello, G Shopp.   

Abstract

During toxicologic evaluation of a dimeric PEG-linked protein, tumor necrosis factor binding protein (TNF-bp), vacuolation of renal cortical tubular epithelium was seen in male and female Sprague-Dawley rats (200-300 g) given i.v. doses of 40, 20, or 10 mg/kg every other day for 3 months. Tubular lesions in rats treated with 20 or 40 mg/kg for 3 months were only partially reversible after a 2-month recovery period. Despite the presence of marked vacuolation, there were no changes in BUN, creatinine, urinalysis parameters, urinary NAG, urinary B2-microglobulin, or fractional sodium excretion. Single i.v. doses > or = 20 mg/kg TNF-bp caused similar but milder changes. However, equivalent doses of PEG alone or the non-PEG-linked TNF-bp did not cause light microscopic evidence of vacuolation. Treatment of rats with another PEG-linked protein of similar molecular weight resulted in similar changes. Immunostaining for TNF-bp revealed positivity in the apical cytoplasm of renal tubular epithelium within 1 h of i.v. dosing. Immunostaining of kidneys from chronically dosed rats indicated that protein was present in some vacuoles as long as dosing continued; however, kidneys from animals on a reversibility study had vacuoles but no immunostaining for TNF-bp. These results, along with a study that showed more severe lesions with PEG-linked proteins of lower molecular weight and minimal if any lesions with PEG-linked proteins > 70 kDa, suggest that TNF-bp is filtered through the glomerulus and that the protein with attached PEG is reabsorbed by the proximal tubules. Vacuolation may be a result of fluid distension of lysosomes due to the hygroscopic nature of PEG. These studies demonstrated that PEG-linked proteins have the capacity to induce renal tubular vacuolation at high doses. However, the change was not associated with alteration of clinical pathology or functional markers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579027     DOI: 10.1006/toxs.1997.2396

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  58 in total

1.  Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.

Authors:  Gerardo M Castillo; Sandra Reichstetter; Elijah M Bolotin
Journal:  Pharm Res       Date:  2011-08-04       Impact factor: 4.200

2.  Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Authors:  Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

Review 3.  Protein-polymer conjugation-moving beyond PEGylation.

Authors:  Yizhi Qi; Ashutosh Chilkoti
Journal:  Curr Opin Chem Biol       Date:  2015-09-07       Impact factor: 8.822

4.  Fully degradable hydrophilic polyals for protein modification.

Authors:  Alexander Yurkovetskiy; Sungwoon Choi; Alexander Hiller; Mao Yin; Catherine McCusker; Sakina Syed; Alan J Fischman; Mikhail I Papisov
Journal:  Biomacromolecules       Date:  2005 Sep-Oct       Impact factor: 6.988

Review 5.  Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

6.  Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Authors:  Haiming Ding; Michelle M Carlton; Stephen P Povoski; Keisha Milum; Krishan Kumar; Shankaran Kothandaraman; George H Hinkle; David Colcher; Rich Brody; Paul D Davis; Alex Pokora; Mitchell Phelps; Edward W Martin; Michael F Tweedle
Journal:  Bioconjug Chem       Date:  2013-10-31       Impact factor: 4.774

7.  A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector.

Authors:  Zhijian He; Lei Miao; Rainer Jordan; Devika S-Manickam; Robert Luxenhofer; Alexander V Kabanov
Journal:  Macromol Biosci       Date:  2015-04-02       Impact factor: 4.979

8.  Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".

Authors:  Gregory Finch; Henry Havel; Mostafa Analoui; Randall W Barton; Anil R Diwan; Meliessa Hennessy; Vijayapal Reddy; Nakissa Sadrieh; Lawrence Tamarkin; Marc Wolfgang; Benjamin Yerxa; Banu Zolnik; Man Liu
Journal:  AAPS J       Date:  2014-05-13       Impact factor: 4.009

9.  Synthesis and self-assembly of well-defined poly(amino acid) end-capped poly(ethylene glycol) and poly(2-methyl-2-oxazoline).

Authors:  Rodolphe Obeid; Carmen Scholz
Journal:  Biomacromolecules       Date:  2011-09-07       Impact factor: 6.988

10.  pH-dependent anticancer drug release from silk nanoparticles.

Authors:  F Philipp Seib; Gregory T Jones; Jelena Rnjak-Kovacina; Yinan Lin; David L Kaplan
Journal:  Adv Healthc Mater       Date:  2013-04-26       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.